Variants of humanized anti-carcinoma monoclonal antibody CC49
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsSyed V. S. Kashmiri, Eduardo A. Padlan, Jeffrey Schlom
Life of this patent
Estimating the term…
Abstract
The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
Claims19
A method of detecting tumor cells expressing TAG-72, comprising:
- contacting cells with a humanized anti-TAG-72 antibody comprising a light chain Complementary Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3;
- and a heavy chain Complementary Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3, wherein L-CDR3, H-CDR1, H-CDR2, and H-CDR3 comprise murine monoclonal CC49 antibody CDRs and at least one of L-CDR1 and L-CDR2 are a human monoclonal LEN antibody L-CDR1 and L-CDR2, and wherein the humanized CC49 antibody retains binding affinity for TAG-72 and has reduced immunogenicity, as compared to a parental humanized CC49 antibody,
- detecting the presence of the humanized antibody bound to TAG-72, thereby detecting the presence of the cell expressing TAG-72.
Dependencies are inferred from the claim text.